Mifegyne

Mifepristone, the active ingredient in Mifegyne, is a progesterone receptor antagonist presented as an oral tablet for oral use. It is employed in the medical termination of intra‑uterine pregnancy and in the management of early pregnancy loss in women. The medication is administered under the guidance of qualified health professionals to ensure safety and efficacy.

GNH USA supplies Mifegyne as a licensed, GDP‑compliant international pharmaceutical supplier, providing quality‑assured products to hospitals, pharmacies and clinics worldwide, with a focus on regulatory adherence and reliable distribution.

Mifegyne (mifepristone) is used in reproductive health for medical termination of pregnancy and early pregnancy loss.

Medical termination of intrauterine pregnancy: induces decidual breakdown and detachment of the gestational sac. Management of early pregnancy loss: facilitates expulsion of retained products of conception. Pre‑treatment before misoprostol in combined regimen: sensitizes the uterus to prostaglandins for effective expulsion.

Mifegyne may cause a range of adverse reactions. Monitoring and appropriate medical supervision are recommended.

Common Side Effects: - Nausea: mild to moderate nausea reported. - Vaginal bleeding: increased bleeding during the treatment course. - Abdominal cramping: uterine cramping and pain. - Fatigue: general feeling of tiredness. - Diarrhea: loose stools or increased bowel movements. - Headache: occasional mild headache.

Serious or Rare Side Effects: - Severe hemorrhage: excessive bleeding that may require medical intervention. - Infection: signs such as fever, chills, or foul‑smelling discharge. - Allergic reaction: rash, itching, swelling, or anaphylaxis in rare cases.

Before using Mifegyne, certain precautions should be observed. - Confirm gestational age: ensure pregnancy is ≤ 9 weeks. - Medical supervision: administration must be under a qualified health professional. - Contraindications: avoid in chronic adrenal failure, long‑term corticosteroid therapy, or anticoagulant use. - Drug interactions: review concomitant medications for potential effects. - Follow‑up care: schedule post‑treatment evaluation to assess completeness. - Store at ambient temperature: keep below 25 °C, retain original packaging, and protect from moisture.

Mifegyne can interact with other medicines; some require avoidance while others need monitoring.

Major Interactions (Avoid): - CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Long‑acting corticosteroids: risk of adrenal insufficiency. - Anticoagulants: increased bleeding risk.

Moderate Interactions (Monitor Closely): - NSAIDs: may intensify uterine cramping. - Macrolide antibiotics: potential modest effect on metabolism. - Azole antifungals: may alter plasma levels of mifepristone.